Genetics of impulse control disorders in Parkinson’s disease

  title={Genetics of impulse control disorders in Parkinson’s disease},
  author={Florence Cormier and Julia Muellner and Jean-Christophe Corvol},
  journal={Journal of Neural Transmission},
Impulse control disorders (ICD) have been recognised in Parkinson’s disease (PD) as adverse effects of dopamine replacement therapy, particularly with dopamine agonists. Although virtually all PD patients are treated with dopaminergic drugs, only a minority will develop hyperdopaminergic states, suggesting predisposing and/or protecting factors. The age at onset, the sex and the dose or type of dopaminergic drugs have been identified as clinical predictive factors. Recent genetic studies have… 

Impulse Control Disorders in Parkinson’s Disease: Pathophysiology, Effect of Genetic Polymorphism and Future Research Directions

The existing evidences suggest that genetic polymorphism in Dopamine receptor D1, D2, D3 and the N-Methyl D Aspartate receptor GRIN2Bare the risk factors for the development of impulse control disorders in Parkinson’s disease.

Impulse control disorders in Parkinson’s disease

Specific evaluation tools have now been designed to better evaluate the severity and impact of impulse control disorders in Parkinson’s disease, although features unique to PD have been identified in patients with ICD.

Neurobiology and clinical features of impulse control failure in Parkinson’s disease

Early screening for neuropsychiatric fluctuations, reduction of DA, fractionating levodopa dosage, education of patients and their relatives, are the key strategies for diagnosis and management of ICDs and related disorders.

Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson’s Disease

Using an advanced statistical approach, SNPs in nine genes, including a novel polymorphism in DRD1, are identified with potential application for the identification of PD patients at risk for ICDs.

Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease

The results show that adding a candidate genetic panel increases ICD predictability, suggesting potential for developing clinical-genetic models to identify patients with PD at increased risk of ICD development and guide DRT management.

Impulse control disorders and related behaviors in Parkinson's disease: risk factors, clinical and genetic aspects, and management

Regular monitoring of ICDRB during the course of Parkinson's disease is needed, particularly in the subject at high risk of developing these complications, and Precision medicine will require the appropriate use of machine learning to be reached in the clinical setting.

Parkinson’s disease management and impulse control disorders: current state and future perspectives

This review mainly focusses on the most common ICDs in the context of currently accepted management strategies for PD and emphasizes areas of controversy in need of further research.

Polymorphisms of Dopamine Receptor Genes and Parkinson’s Disease: Clinical Relevance and Future Perspectives

The role of DR in the modulation of peripheral immunity, in light of the emerging role of the peripheral immune system in PD pathophysiology, is examined.

A systematic review of impulse control disorders in Parkinson's disease.

A systematic overview of literature published between 2000 and January 2013 reporting impulse control disorders in Parkinson's disease is presented and prevalence rates and the functional neuroanatomy, the impact of dopamine-serotonin interactions, and the cognitive symptomatology associated with impulse control Disorders in Parkinson’s disease are discussed.



Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Dopamine agonist treatment in PD is associated with 2- to 3.5-fold increased odds of having an ICD, which represents a drug class relationship across ICDs.

Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease

Variants of DRD3 p.S9G and GRIN2B c.366C>G may be associated with the appearance of ICRB in PD, and carriage of either AA genotype ofDRD3 or CC genotypes of GRin2B was identified as an independent risk factor for I CRB.

Association of attention-deficit disorder and the dopamine transporter gene.

Attention-deficit hyperactivity disorder (ADHD) has been shown to be familial and heritable, in previous studies. As with most psychiatric disorders, examination of pedigrees has not revealed a

Dopamine Genes and Pathological Gambling in Discordant Sib-Pairs

The results suggest the association of PG with DRD1 −800 T/C allele T (P = .03) and the dopamine transporter gene (SCL6A3 40 bp VNTR).

Genetics of dopamine receptors and drug addiction: a comprehensive review

Overall, this review indicates that different aspects of the addiction phenotype are critically influenced by dopaminergic receptors and that variants of those genes seem to influence some addiction phenotypes in humans.

Genetics of dopamine receptors and drug addiction

Dopamine plays a key role in reward behavior, yet the association of drug dependence as a chronic, relapsing disorder with the genes encoding the various dopaminergic receptor subtypes remains

Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder.

The present findings suggest that polymorphic variation in the gene encoding the D4 dopamine receptor may be a contributing factor in the expression of symptoms associated with ADHD.